Form 4: Neurocrine Biosciences Director Richard F. Pops Executes Stock Options and Sells Shares

Director Richard F. Pops exercised stock options and sold Neurocrine Biosciences shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard F. Pops, a director of Neurocrine Biosciences, executed non-qualified stock options and sold shares of common stock.
• On March 8, 2024, Pops exercised options to acquire 1,700 shares at a price of $42.76 and sold the same amount at a weighted average price of $140.0459.
• On March 11, 2024, Pops exercised options to acquire 100 shares at a price of $42.76 and sold the same amount at a price of $140.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 21, 2023.
• Following these transactions, Pops directly owns 29,512 shares of Neurocrine Biosciences common stock and 23,200 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily reflect a change in the director's outlook on the company. The sales are at a price significantly higher than the exercise price.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate insider knowledge.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing execution of the 10b5-1 trading plan suggests continued sales of shares by the reporting person.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Monitoring these transactions provides insights into management's perspective on the company's value.

Comparison to Industry Standards

• It is common for directors of publicly traded companies, such as Neurocrine Biosciences, to have stock option grants as part of their compensation packages.
• The use of 10b5-1 trading plans is a standard practice among corporate insiders to sell shares over time while avoiding accusations of insider trading.
• Comparing the trading activity of Richard F. Pops to that of other directors in similar biotech companies would provide a more comprehensive understanding of whether these transactions are typical or unusual.

Stakeholder Impact

• The transactions could have a minor impact on shareholders if the market perceives the sales negatively, although the 10b5-1 plan mitigates this concern.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates